Mark Neumann's Insider Trades & SAST Disclosures
Mark Neumann's most recent trade in Intra-Cellular Therapies Inc was a trade of 13,133 Common Stock done . Disclosure was reported to the exchange on March 6, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mark Neumann.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 13,133 | 54,154 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 13,133 | 13,133 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 7,345 | 0 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 7,345 | 55,927 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 131.19 per share. | 06 Mar 2025 | 5,572 | 48,582 (0%) | 0% | 131.2 | 730,991 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 131.24 per share. | 06 Mar 2025 | 3,116 | 52,811 (0%) | 0% | 131.2 | 408,944 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 8,742 | 44,730 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 8,742 | 17,485 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 128.20 per share. | 01 Mar 2025 | 3,709 | 41,021 (0%) | 0% | 128.2 | 475,494 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 22,727 | 22,727 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 11,017 | 40,717 (0%) | 0% | 0 | Common Stock | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 127.00 per share. | 31 Jan 2025 | 4,729 | 35,988 (0%) | 0% | 127 | 600,583 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.89 per share. | 16 Aug 2024 | 18,714 | 48,414 (0%) | 0% | 36.9 | 690,359 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2024 | 18,714 | 0 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 75.08 per share. | 16 Aug 2024 | 18,714 | 29,700 (0%) | 0% | 75.1 | 1,405,047 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 66.37 per share. | 07 Mar 2024 | 8,636 | 34,196 (0%) | 0% | 66.4 | 573,171 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 7,345 | 7,345 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 7,345 | 37,045 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 66.95 per share. | 07 Mar 2024 | 4,496 | 29,700 (0%) | 0% | 66.9 | 301,007 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 65.11 per share. | 07 Mar 2024 | 4,303 | 32,742 (0%) | 0% | 65.1 | 280,168 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 65.92 per share. | 07 Mar 2024 | 1,729 | 31,013 (0%) | 0% | 65.9 | 113,976 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 66.86 per share. | 07 Mar 2024 | 1,313 | 29,700 (0%) | 0% | 66.9 | 87,787 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 13,132 | 26,266 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 13,132 | 42,832 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 26,227 | 26,227 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 7,907 | 0 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Neumann Mark | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 7,907 | 37,607 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Neumann Mark | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 69.56 per share. | 23 Feb 2024 | 4,059 | 33,348 (0%) | 0% | 69.6 | 282,344 | Common Stock |
| Intra-Cellular Therapies Inc | Neumann Mark | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 70.70 per share. | 23 Feb 2024 | 2,341 | 31,007 (0%) | 0% | 70.7 | 165,509 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 71.18 per share. | 23 Feb 2024 | 1,307 | 29,700 (0%) | 0% | 71.2 | 93,032 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 68.03 per share. | 23 Feb 2024 | 200 | 37,407 (0%) | 0% | 68.0 | 13,606 | Common Stock |
| Intra-Cellular Therapies Inc | Neumann Mark | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 11,860 | 41,560 (0%) | 0% | 0 | Common Stock | |
| Intra-Cellular Therapies Inc | Neumann Mark | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 67.49 per share. | 01 Feb 2024 | 6,904 | 29,700 (0%) | 0% | 67.5 | 465,951 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 66.67 per share. | 01 Feb 2024 | 4,956 | 36,604 (0%) | 0% | 66.7 | 330,417 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2023 | 55,300 | 0 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 58.79 per share. | 07 Aug 2023 | 55,300 | 45,339 (0%) | 0% | 58.8 | 3,251,087 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.59 per share. | 07 Aug 2023 | 55,300 | 100,639 (0%) | 0% | 18.6 | 1,028,027 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 54.01 per share. | 28 Mar 2023 | 10,183 | 45,339 (0%) | 0% | 54.0 | 549,984 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 54.86 per share. | 28 Mar 2023 | 5,421 | 55,522 (0%) | 0% | 54.9 | 297,396 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 16,708 | 65,907 (0%) | 0% | 0 | Common Stock | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 7,344 | 14,690 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 7,344 | 64,701 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 43.50 per share. | 09 Mar 2023 | 6,750 | 59,157 (0%) | 0% | 43.5 | 293,625 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 45.10 per share. | 09 Mar 2023 | 3,335 | 61,366 (0%) | 0% | 45.1 | 150,409 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 42.74 per share. | 09 Mar 2023 | 1,800 | 57,357 (0%) | 0% | 42.7 | 76,932 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 44.05 per share. | 09 Mar 2023 | 423 | 60,943 (0%) | 0% | 44.0 | 18,633 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 39,398 | 39,398 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 50.01 per share. | 01 Mar 2023 | 7,241 | 49,199 (0%) | 0% | 50.0 | 362,122 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 7,906 | 60,486 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 7,906 | 7,907 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 47.12 per share. | 23 Feb 2023 | 4,046 | 56,440 (0%) | 0% | 47.1 | 190,648 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 11,139 | 0 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 11,139 | 56,478 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 46.61 per share. | 18 Feb 2023 | 3,140 | 53,338 (0%) | 0% | 46.6 | 146,355 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 48.93 per share. | 18 Feb 2023 | 635 | 52,580 (0%) | 0% | 48.9 | 31,071 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 47.32 per share. | 18 Feb 2023 | 123 | 53,215 (0%) | 0% | 47.3 | 5,820 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2022 | 86,348 | 0 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.73 per share. | 08 Apr 2022 | 86,348 | 131,687 (0%) | 0% | 12.7 | 1,099,210 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 64.42 per share. | 08 Apr 2022 | 53,987 | 60,224 (0%) | 0% | 64.4 | 3,477,843 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 63.55 per share. | 08 Apr 2022 | 17,476 | 114,211 (0%) | 0% | 63.6 | 1,110,600 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 65.14 per share. | 08 Apr 2022 | 14,885 | 45,339 (0%) | 0% | 65.1 | 969,609 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 22,034 | 22,034 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 17,916 | 17,916 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 11,139 | 11,139 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 11,139 | 56,478 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 55.60 per share. | 18 Feb 2022 | 6,532 | 49,946 (0%) | 0% | 55.6 | 363,179 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 54.84 per share. | 18 Feb 2022 | 4,607 | 45,339 (0%) | 0% | 54.8 | 252,648 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2022 | 20,948 | 0 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2022 | 20,948 | 66,287 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 40.80 per share. | 08 Jan 2022 | 13,935 | 49,591 (0%) | 0% | 40.8 | 568,548 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 40.09 per share. | 08 Jan 2022 | 4,252 | 45,339 (0%) | 0% | 40.1 | 170,463 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 41.74 per share. | 08 Jan 2022 | 2,761 | 63,526 (0%) | 0% | 41.7 | 115,244 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2021 | 13,448 | 0 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2021 | 13,448 | 58,787 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 41.49 per share. | 15 Oct 2021 | 6,702 | 52,085 (0%) | 0% | 41.5 | 278,066 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 40.77 per share. | 15 Oct 2021 | 4,288 | 47,797 (0%) | 0% | 40.8 | 174,822 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 39.44 per share. | 15 Oct 2021 | 1,958 | 45,839 (0%) | 0% | 39.4 | 77,224 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 38.88 per share. | 15 Oct 2021 | 500 | 45,339 (0%) | 0% | 38.9 | 19,440 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2021 | 23,719 | 23,719 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2021 | 18,714 | 18,714 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2021 | 11,139 | 22,278 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2021 | 11,139 | 50,523 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 39.26 per share. | 18 Feb 2021 | 4,584 | 45,939 (0%) | 0% | 39.3 | 179,968 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 38.90 per share. | 18 Feb 2021 | 600 | 45,339 (0%) | 0% | 38.9 | 23,340 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2021 | 20,948 | 20,948 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2021 | 20,948 | 49,068 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 32.02 per share. | 08 Jan 2021 | 9,684 | 39,384 (0%) | 0% | 32.0 | 310,082 | Common Stock |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2020 | 13,448 | 13,448 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2020 | 13,448 | 34,912 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Mark Neumann | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 26.80 per share. | 15 Oct 2020 | 6,792 | 28,120 (0%) | 0% | 26.8 | 182,026 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges